News Posts List
Final results of a prospective phase II trial
06/24/2011
We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy. 42% of the patients had been systemically pre-treated.
Seattle Genetics' Paradigm In Waiting
06/24/2011
SGN-75, undergoing a phase I trial for metastatic renal cell carcinoma...
Pivotal Phase III Trial With IMA901
06/24/2011
igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
Is your family at greater risk for kidney cancer?
06/19/2011
Reliable data on familial risks are important for clinical counseling and cancer genetics.
The Economist: The costly war on cancer
06/19/2011
New cancer drugs are technically impressive. But must they cost so much?
ASCO Annual Meeting: Kidney Cancer Abstracts
06/19/2011
Information about renal cell carcinoma may be found in these abstracts that were presented recently at the world's largest oncology meeting, held in Chicago. The Kidney Cancer Association sponsored the presentation of this information.
DF/HCC Kidney Cancer Program
06/16/2011
New Cancer Drugs Reach Patients Sooner In The United States Than In Europe
06/16/2011
We conducted a direct drug-to-drug comparison of the two regulatory agenciesÂ’ approvals of new oncology drugs.
First Patients are Vaccinated in IMPRINT Phase III Trial
06/15/2011
tthe first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
News Feed